About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, 4
Alkermes plc News and around…
Latest news about Alkermes plc (ALKS) common stock and company :
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
Image provided by BioCorRx of a naltrexone pellet This post contains sponsored advertising content. This content is for informational ...
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication ...
Alkermes, Tesla, Nucor Corp. and GoPro are highlighted in this Screen of the Week article.
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.
Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..
Here are four top-ranked liquid stocks, Alkermes (ALKS), Tesla (TSLA), Nucor (NUE) and GoPro (GPRO), which investors can tap for healthy returns.
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered
Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alkermes plc (ALKS), where a total volume of 5,564 contracts has been traded thus far today, a contract volume which is representative of approximately 556,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.6% of ALKS's average daily trading volume over the past month, of 982,740 shares..
BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
Before it even turned Monday in the West, China insurers were feeling the heat.
Starting a new year - we look at tech, pharma and mining stocks and their goings-on.
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV (NYSE:ASR) from Sell ...